Towards the overcoming of anticancer drug resistance mediated by p53 mutations.

Cao, Xin; Hou, Jiayun; An, Quanlin; Assaraf, Yehuda G; Wang, Xiangdong

Cao, Xin; Hou, Jiayun; An, Quanlin; Assaraf, Yehuda G; Wang, Xiangdong.

Affiliation

Cao X; Zhongshan Hospital Institute of Clinical Science, Fudan University Shanghai Medical College, Shanghai, 200032, China. Electronic address: caox@fudan.edu.cn.
Hou J; Zhongshan Hospital Institute of Clinical Science, Fudan University Shanghai Medical College, Shanghai, 200032, China.
An Q; Zhongshan Hospital Institute of Clinical Science, Fudan University Shanghai Medical College, Shanghai, 200032, China.
Assaraf YG; The Fred Wyszkowski Cancer Research Lab, Department of Biology, Technion-Israel Institute of Technology, Haifa, 3200003, Israel. Electronic address: assaraf@technion.ac.il.
Wang X; Zhongshan Hospital Institute of Clinical Science, Fudan University Shanghai Medical College, Shanghai, 200032, China. Electronic address: xiangdong.wang@clintransmed.org.

Drug Resist Updat ; 49: 100671, 2020 03.

Article de En | MEDLINE | ID: mdl-31841768

Sujet(s)
Mots clés

Cancer; Chemotherapy; Drug resistance; Mutations; Novel targeted cancer treatments; Overcoming chemoresistance; p53

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Protéine p53 suppresseur de tumeur / Tumeurs / Antinéoplasiques Limites: Animals / Humans Langue: En Journal: Drug Resist Updat Sujet du journal: ANTINEOPLASICOS Année: 2020 Type de document: Article Pays de publication: Royaume-Uni

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google